Global Wellness Pharma Subsidiary Supports Cancer Therapeutic Company AVM Biotechnology
Global Wellness Pharma Subsidiary Supports Cancer Therapeutic Company AVM Biotechnology
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X) (OTCQB: GWSFF) ("Global Wellness" or the "Company") pharma subsidiary is excited to work with BioMed360 a GWS medical advisor.
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年12月5日)-全球健康戰略公司(CSE：GWS)(FSE：O3X)(OTCQB：GWSFF)(“全球健康”或“公司”)製藥子公司很高興能與GWS醫療顧問BioMed360合作。
GWS pharma subsidiary is focused on providing companies with financial, operational, and management assistance during their clinical trials phase. GWS announces that BioMed360 Solutions Corp signed a letter of intent for the 100% acquisition of AVM Biotechnology. AVM Biotechnology is developing and advancing a proprietary formulation of its unique molecule AVM0703. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body's supercharged gamma delta+ Natural Killer T-like (AVM-NKT) immune cells. These AVM-NKT cells have unique immune response properties in comparison to ordinary T-cells and rapidly appear following a single AVM0703 dose. Pre-clinical and early clinical data indicate that these cells could play a significant role in several diseases and conditions.
GWS製藥子公司專注於在公司的臨牀試驗階段為公司提供財務、運營和管理援助。GWS宣佈，BioMed360 Solutions Corp簽署了100%收購AVM Biotech的意向書。AVM生物技術公司正在開發和推進其獨特分子AVM0703的專利配方。這種配方允許非常高的劑量，以激活釋放和觸發體內增壓的伽馬三角洲+自然殺傷T樣免疫細胞(AVM-NKT)的產生。與普通T細胞相比，這些AVM-NKT細胞具有獨特的免疫反應特性，在單劑AVM0703劑量後迅速出現。臨牀前和早期臨牀數據表明，這些細胞可能在幾種疾病和條件下發揮重要作用。
"Immunotherapy causes fewer side effects than other treatments, because it targets just your immune system and not all the cells in your body. Immunotherapies help to slow, stop and kill cancerous cells, and for some patients can be safer and more effective than even chemotherapy and radiation. Our mission at Global Wellness has always been to embrace health and wellness, and we look forward to assisting BioMed 360 and AVM Biotechnology with their clinical trials capital needs," said Meris Kott, CEO Global Wellness Strategies Inc.
Global Wellness Strategy Inc.首席執行官Meris Kott表示：“與其他療法相比，免疫療法產生的副作用更少，因為它只針對你的免疫系統，而不是你體內的所有細胞。免疫療法有助於減緩、阻止和殺死癌細胞，對一些患者來説，甚至比化療和放射更安全、更有效。我們在Global Wellness的使命一直是擁抱健康和健康，我們期待着幫助BioMed 360和AVM Biotech進行臨牀試驗，以滿足資金需求。”
About Global Wellness Strategies:
Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.
關於全球健康戰略：
Global Wellness Strategy是一個前景創造者，在快速增長的健康消費品市場為高增長的公司提供財務、運營和管理方面的幫助。該公司專注於全球健康、迷幻藥、真菌學、大麻和CBD，以及與醫療保健相關的目標公司。
For further information visit websites:
欲瞭解更多信息，請訪問以下網站：
Or Contact Meris Kott CEO 604.484.0355 or email to info@globalwellnessstrategies.com
或聯繫Meris Kott首席執行官604.484.0355，或發送電子郵件至info@global alwell nessstrategies.com
Further information about the Company is available on under the Company's profile.
欲瞭解更多有關本公司的信息，請訪問：本公司簡介。
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
加拿大證券交易所及其監管服務提供商(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。本新聞稿中包含的某些陳述可能構成“前瞻性陳述”或“前瞻性信息”(統稱為“前瞻性信息”)，因為這些術語在1995年的“私人證券訴訟改革法”和類似的加拿大法律中使用。這些陳述與未來的事件或未來的表現有關。使用“可能”、“打算”、“預期”、“相信”、“將”、“預計”、“估計”、“預期”以及與非歷史事實有關的類似表述和陳述，旨在識別前瞻性信息，並基於公司對此類未來事件的結果和時機的當前信念或假設。未來的實際結果可能會有很大不同。特別是，本新聞稿包含與該公司的業務、其融資和某些公司變化有關的前瞻性信息。本新聞稿中包含的前瞻性信息是截至本新聞稿發佈之日的信息，公司沒有義務因新信息、未來事件或其他原因而更新或修改任何前瞻性信息，除非適用的證券法要求這樣做。由於本文包含的風險、不確定性和假設，投資者不應過度依賴前瞻性信息。上述陳述明確表示，本文中包含的任何前瞻性信息都是合格的。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。